Pharmaco-electroencephalography research using neurological data from clinical EEG and qEEG technologies could improve medication selection and treatment planning in psychiatry. Over the past 5 years in a multidisciplinary practice, 386 refractory cases have been found to contain a small number of brainwave abnormalities related to the following diagnostic categories: mood, anxiety, Autism Spectrum Disorder, and Attention Deficit Hyperactivity Disorder. The brainwave abnormalities were the following: encephalopathy, focal slowing, beta spindles, and transient discharges. However, results found that although these abnormalities were noted in the majority of cases with medication failure they did not align directly with specific diagnoses. These findings suggest that data from the EEG and qEEG can help guide individualized medicine selection and treatment planning, especially when previous medications have failed.